Market Overview

Nvidia Seeing Strong Trends Heading Into Next Quarterly Print

Nvidia Seeing Strong Trends Heading Into Next Quarterly Print

Analysts at Mizuho Securities turned incrementally bullish on NVIDIA Corporation (NASDAQ: NVDA) for three key reasons. The firm's Vijay Rakesh maintains a Buy rating on Nvidia's stock boosted from $180 to $220.

First, Nvidia's exposure to the cryptocurrency and gaming sectors remains strong, Rakesh commented in a research report. Specifically, a fact-finding trip to Asia revealed shipments of GPU and motherboard devices had risen 50 percent quarter over quarter versus the prior "just flat." Meanwhile, GPU pricing has been trending higher for much of the quarter and represents another tailwind for Nvidia.

Second, Nvidia likely began shipping its Volta V100's during the second week of July and likely realized new design wins among Chinese clients, including Tencent, Alibaba Group Holding Ltd (NYSE: BABA) and Baidu Inc (ADR) (NASDAQ: BIDU).

Third, Nvidia's exposure to the automotive segment remains strong as well, the analyst continued. While Drive PX and Drive PX2 are still priced at a premium, the acceleration in the autonomous roadmap bodes well for Nvidia.

Finally, the analyst's incremental bullish stance on Nvidia is based on a 55x multiple on the company's fiscal 2019 earnings per share estimate and the assumption the company grows into a $20 to $30 billion data center/automotive total addressable market from just $1.8 billion in DC revenue today.

Related Links:

Nvidia Expands Lead In AI-Driven Vehicle Suppliers With New Products, New Partnerships

Robotics Analyst: Nvidia's AI Developments Don't Change The Self-Driving Car Timeline

Latest Ratings for NVDA

Nov 2019MaintainsHold
Nov 2019MaintainsBuy
Oct 2019MaintainsOutperform

View More Analyst Ratings for NVDA
View the Latest Analyst Ratings

Posted-In: Analyst Color Earnings Long Ideas News Guidance Upgrades Price Target Previews Best of Benzinga


Related Articles (BIDU + BABA)

View Comments and Join the Discussion!

A Proxy Fight With Marcato Isn't A Good Enough Reason To Buy Deckers Outdoor

Cara Therapeutics Higher Off Meeting With FDA